Scientific deep-dive
GLP-1 Drugs, Diabetic Foot Ulcers and Blood Flow to the Foot
A randomized trial found liraglutide raised oxygen reaching the skin of the lower limb, with 89% of the drug group improving against 46% of controls. A 125,150-person cohort recorded amputation in 2.34% of semaglutide users against 5.21%.
In people with type 2 diabetes and peripheral artery disease, six months of liraglutide raised the oxygen reaching the skin of the lower limb. Eighty-nine percent of the drug group hit a 10% improvement in transcutaneous oxygen pressure, against 46% on conventional risk-factor treatment.[1] That is a mechanism, measured with an instrument. Separately, a cohort of 125,150 people with diabetic foot ulcers found amputation recorded in 2.34% of semaglutide users against 5.21% of non-users — an association, in a study whose authors say plainly that causation cannot be inferred.[2]
The randomized half: oxygen reaching the foot
STARDUST enrolled 55 people in Naples with type 2 diabetes, peripheral artery disease and a transcutaneous oxygen pressure between 30 and 49 mm Hg — the band where perfusion is impaired but the limb is not yet critically threatened. They were randomized to 1.8 mg liraglutide or conventional treatment of cardiovascular risk factors for six months.[1]
| Measure | Result | 95% CI |
|---|---|---|
| Transcutaneous oxygen pressure | +11.2 mm Hg | 8.0 to 14.5 (P < .001) |
| Reached a 10% rise in TcPo₂ | 89% vs 46% | RR 1.91 (1.26–2.90) |
| 6-minute walking distance | +25.1 m | 21.8 to 28.3 (P < .001) |
| C-reactive protein | −0.4 mg/dL | −0.7 to −0.07 |
| Urinary albumin-to-creatinine ratio | −119.4 mg/g | −195.0 to −43.8 |
The walking distance is the line worth pausing on, because it is the one a person would notice. Twenty-five meters further in six minutes is a change in what the day can contain.
The observational half: what happened to the feet
A retrospective cohort drew on the TriNetX US research network across 64 healthcare organizations, comparing 6,329 semaglutide users who had a diabetes-related foot ulcer against 118,821 non-users, matched on age, sex, race and ethnicity. Within one year:[2]
| Outcome | Semaglutide | No semaglutide |
|---|---|---|
| Amputation | 2.34% | 5.21% |
| Chronic non-healing wound | 0.75% | 1.23% |
| Wound healing complications | 0.19% | 0.38% |
| Wound dehiscence | 0.26% | 0.56% |
| Chronic pain | 4.44% | 8.06% |
| Wound care | 2.42% | 4.86% |
Similar patterns held out to five years. But this is a records study, and the direction of the confounding is not obvious: people prescribed semaglutide differ from people who are not, in ways a match on age, sex, race and ethnicity does not capture. Whoever is well enough to be started on a weekly injectable may also be whoever was going to keep their foot.
Causation cannot be inferred due to the study’s observational design.— Lewis et al., Diabetes & Vascular Disease Research, 2025
How to hold the two together
A trial that shows a plausible mechanism and a cohort that shows the outcome you would expect from that mechanism is a stronger position than either on its own. It is still not proof. Nobody has run a randomized trial with amputation as the endpoint, which is the study that would settle it, and until somebody does the honest description is “consistent and unproven”.
What it is not is a reason to start a GLP‑1 to treat a foot ulcer. Neither drug is approved for that, ulcer care is wound care, and the people in both studies were being treated for diabetes. If you have an ulcer, the person to talk to is whoever is dressing it. Our page on GLP-1s and your kidneys covers the other microvascular complication where this class has randomized outcome data, and the methodology explains how we weigh a records study against a trial.
Frequently Asked Questions
References
- 1.Caruso P, Maiorino MI, Longo M, et al. Liraglutide for Lower Limb Perfusion in People With Type 2 Diabetes and Peripheral Artery Disease: The STARDUST Randomized Clinical Trial JAMA Network Open. 2024. PMID: 38470420.
- 2.Lewis JE, Omenge DK, Patterson AR, et al. The impact of semaglutide on wound healing in diabetes related foot ulcer patients: A TriNetX database study Diabetes & Vascular Disease Research. 2025. PMID: 40080656.
Related research
Beyond the Scale: Blood Pressure, Lipids and What Else Changes
Pooling the individual records of 3,136 people, systolic blood pressure fell 4.95 mmHg further than placebo — and by about the same amount whether or not the person had hypertension.
7 min read
Does Semaglutide Slow Aging?
A trial reported semaglutide slowing epigenetic aging across several clocks. It was a post hoc analysis in an HIV-specific cohort over 32 weeks — and '−4.9 years per year' is a rate, not age removed.
5 min read
Dry Mouth on a GLP-1: Three Published Cases, and What to Tell Your Dentist
The published evidence that GLP-1 drugs cause dry mouth is three case reports. Nobody has measured how often it happens — but reduced saliva raises decay risk regardless of cause, which is the part worth acting on.
5 min read
Eating Too Little on a GLP-1: What the Deficiency Data Show
Across 480,825 adults, more than 60% were consuming below estimated requirements, vitamin D deficiency reached 13.6% at a year, and ferritin ran 26–30% below an active comparator.
7 min read
GLP-1 Drugs After 65: Strength, Not Just Weight
Grip strength held up in general adult trials even as lean mass fell. In older adults with type 2 diabetes, prolonged use has been linked to the opposite — and no guidelines exist for this age group.
7 min read
GLP-1 Drugs After Spinal Cord Injury: Three People Treated, Two Not
In a controlled case series of five people with chronic spinal cord injury, three on weekly semaglutide lost weight, fat mass and visceral fat over 26 weeks while the two untreated participants gained on every measure.
5 min read
Where to get semaglutide (Ozempic / Wegovy) online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Luvo Health
Moving between compounded and brand without changing seller
From $249/mo
Get started →Strut Health
Semaglutide at $99/month, 48% under the register median
From $99/mo
Get started →Pallas Health
Knowing which pharmacy fills the vial — it names Belmar Pharmacy
From $199/mo
Get started →